Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Skin Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Carcinoma 1

Interventions

Specimen Handling 629pembrolizumab 559Magnetic Resonance Spectroscopy 539Carboplatin 423Cyclophosphamide 371Cisplatin 371Biopsy 357Paclitaxel 304Nivolumab 301Gemcitabine 299Radiotherapy 270Bevacizumab 238Dexamethasone 207fludarabine 205Docetaxel 189durvalumab 178atezolizumab 176Oxaliplatin 172Fluorouracil 167venetoclax 164Rituximab 164Pemetrexed 162Radiation 159Doxorubicin 159Capecitabine 158Radiosurgery 147Etoposide 137Ipilimumab 134Leucovorin 133Lenalidomide 130

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
MAPRE1 protein, human × 90 days × Clear all
NCT04349436 2026-04-22

ARTACUS

Replimune, Inc.

Phase 1/2 Active not recruiting
69 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell

NCT06216938 2026-04-13

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

University of Pittsburgh

Phase EARLY_PHASE1 Recruiting
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡